Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs SOR C13 (Primary)
- Indications Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Soricimed Biopharma
- 01 Feb 2017 Results published in the Investigational New Drugs
- 27 Sep 2016 According to a Soricimed Biopharma media release, the US FDA has granted orphan drug designation to SOR-C13 for the treatment of pancreatic cancer.
- 06 Jul 2016 Results published in Soricimed Biopharma media release.